Compass Pathways PLC - American Depository Shares (CMPS) closed at $9.18 on November 9, 2026, up 6.6% from the previous close, on volume of 3,215,117 shares (30-day average 3,252,590).
Data as of November 9, 2026.
| # | Date | Strategy | Legs | Contracts |
|---|---|---|---|---|
| 1 | Oct 26, 2026 | Call Spread | 21-May-2712 : 20 C | 6,960 |
| 2-3 | The next 2 largest trades are for Premium members. Start a 7-day free trial | |||
Ranked by contracts: multi-leg trades of 200 or more contracts on one day, through Nov 9, 2026. See the 10 largest for 30, 60 and 90 days
DEA looks to increase legal psychedelics production for medical research
Seeking Alpha News (Tue, 10-Nov 10:45 AM ET)
TipRanks (Tue, 10-Nov 6:15 AM ET)
RBC Capital Reaffirms Their Buy Rating on COMPASS Pathways (CMPS)
TipRanks (Mon, 9-Nov 8:48 PM ET)
J&J gets into psychedelic treatments with backing of Delix Therapeutics
Seeking Alpha News (Mon, 9-Nov 12:12 PM ET)
Cathie Wood's Ark Invest buys $96M of SpaceX, adds to Nvidia and AMD; trims Broadcom
Seeking Alpha News (Mon, 9-Nov 7:05 AM ET)
TipRanks (Mon, 9-Nov 6:40 AM ET)
Business Wire (Mon, 9-Nov 6:30 AM ET)
Compass Pathways’ Commercial Preparation Supports Outlook Despite Price-Target Cut to $16
TipRanks (Fri, 6-Nov 2:36 PM ET)
Compass Pathways Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Business Wire (Thu, 5-Nov 4:30 PM ET)
Compass Pathways to Participate in Stifel 2026 Healthcare Conference on November 11th
Business Wire (Wed, 4-Nov 6:30 AM ET)
Compass Pathways PLC is a biotechnology company focused on developing therapies for mental health conditions. Its research centers on a proprietary synthetic psilocybin formulation, COMP360, which is administered alongside psychological support. The company is conducting clinical trials to evaluate the safety and efficacy of this treatment in patients with treatment-resistant depression and other mental health disorders. The company operates in one operating segment.
Compass Pathways PLC - American Depository Shares trades on the NASDAQ stock market under the symbol CMPS.
As of November 10, 2026, CMPS stock price declined to $9.12 with 614,841 million shares trading.
CMPS has a beta of 2.93, meaning it tends to be more sensitive to market movements. CMPS has a correlation of 0.18 to the broad based SPY ETF.
CMPS has a market cap of $1.23 billion. This is considered a Small Cap stock.
In the last 3 years, CMPS traded as high as $15.87 and as low as $2.25.
The top ETF exchange traded funds that CMPS belongs to (by Net Assets): ARKG, IBB, PSIL, SBIO, TMSL.
CMPS has outperformed the market in the last year with a return of +67.3%, while the SPY ETF gained +12.4%. However, in the most recent history, CMPS shares have underperformed the stock market with its stock returning -32.6% in the last 3 month period and -17.5% for the last 2 week period, while SPY has returned -3.2% and -2.5%, respectively.
CMPS support price is $8.77 and resistance is $9.59 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that CMPS shares will trade within this expected range on the day.
